IFNB1 and AL amyloidosis: A recent systematic review of preclinical data demonstrated that VSV-IFNβ consistently reduces neurotoxicity while maintaining robust antitumor activity across various cancer models, including melanoma, hepatocellular carcinoma, and multiple myeloma [57].